Modulight

Company report

02/26/2024 07:20



Antti Siltanen +358 45 119 6869 antti.siltanen@inderes.fi



✓ Inderes corporate customer



We want more visibility

We reiterate our Reduce recommendation and lower our target price to EUR 0.90 (was 1.20). Modulight's revenue was already known after the profit warning. EBIT was clearly below our forecast, mainly due to surprisingly high depreciation but also higher costs than expected. There are no concrete signs of a turnaround yet, so we lowered our forecasts for the coming years. We expect Modulight to continue to grow in the coming years with new commercializations. The result will also improve, but remain loss-making without faster growth than we forecast. The valuation of the stock has moderated, but due to the loss-making and lack of visibility, the risk/reward ratio is modest.

Projects progressed, but revenue is not expected to materialize until the longer term

Modulight reported that several R&D projects had entered clinical phase III during 2023. We expected immediate and substantial revenue from these types of projects, but this did not happen. In the earnings call, the company said that revenue should materialize over a longer time. Modulight repeated the information that several projects are close to the commercialization phase. Considering what the company has announced earlier, commercializations have been delayed and there is no concrete information on its financial value.

Revenue and earnings decreased in 2023

Modulight's revenue stood at 1.0 MEUR (Q4'22: 1.3 MEUR) which was already known after the profit warning at the turn of the year. Full-year revenue of 4.0 MEUR decreased by -12% compared to 2022 (4.6 MEUR). Q4'23 EBIT of -5.1 MEUR was significantly lower than our expectations (-2.3 MEUR). The underperformance is primarily due to depreciation, the amount of which increased strongly compared to previous earnings reports. Operating expenses were also somewhat higher than we expected, which explains a smaller share of the forecast undershoot. Cash flow from operating activities in Q4 was -7.3 MEUR and investments -9.7 MEUR. Due to negative cash flow, Modulight's net cash assets decreased to 18.6 MEUR from 35.6 MEUR in the previous year. The balance sheet remains strong, but the rapid contraction of the cash position and the expected losses reduce the financial leeway.

Forecasts cut as commercialization is delayed and short-term potential falls short of our expectations

Modulight's existing business has been shrinking for the past three years. The company expects growth from new commercializations, but the report did not provide much additional visibility. The company provided no numerical outlook for 2024. We lower our revenue forecasts for 2024-2025 by some 20% due to delays in commercialization. The short-term potential of clinical phase II/III projects has also proven lower than previously expected. Revenue should materialize over the longer term, but there is no visibility for this. Our EBIT forecasts fall sharply due to a clear increase in forecasted depreciation. Otherwise, we only made minor adjustments to our cost forecasts.

The valuation picture is not yet attractive in the absence of evidence of growth

The valuation relies heavily on future projections, which carry an exceptionally high degree of forecasting risk. EV/S ratios are 4.4x-4.0x for 2024-2025 and continue to be above those of the peers. The DCF model indicates a reasonable upside in the stock if strong growth is realized. The stock does not seem unreasonably priced, but due to heavy losses and low visibility, the risk/reward ratio remains modest.

Recommendation

Reduce

(previous Reduce)

EUR 0.90

(previous EUR 1.20)

Share price:

0.85



Key figures

| | 2023 | 20246 | 2025e | 2026e |
|------------------|----------|----------|---------|---------|
| Revenue | 4.0 | 6.5 | 8.8 | 11.5 |
| growth-% | -12% | 62% | 35% | 30% |
| EBIT adj. | -12.1 | -10.5 | -5.5 | -3.3 |
| EBIT-% adj. | -301.4 % | -161.4 % | -62.4 % | -28.9 % |
| Net Income | -11.8 | -10.3 | -4.3 | -2.6 |
| EPS (adj.) | -0.28 | -0.24 | -0.10 | -0.06 |
| | | | | |
| P/E (adj.) | neg. | neg. | neg. | neg. |
| P/B | 0.7 | 0.8 | 0.9 | 0.9 |
| Dividend yield-% | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| | | | | |

neg.

neg.

4.6

neg.

neg.

4.0

neg.

>100

3.4

neg.

neg.

4.9

Source: Inderes

EV/EBIT (adj.)

EV/EBITDA

EV/S

Guidance

Modulight does not provide any guidance.

Share price




Source: Millistream Market Data AB

Revenue and EBIT-%



Source: Inderes

EPS and dividend



Source: Inderes

Value drivers

- A defensive market with growth well into the future
- The company's technological expertise, ability to tailor products and build cloud services gives Modulight a competitive advantage
- A model based on license fees and pay-pertreatment pricing can be highly scalable if successful



Risk factors

- The project-based model has been unreliable, at least for 2022-2023, and we believe its long-term performance requires further evidence.
- Revenue and profitability are poorly predictable
- Low visibility of projects and their progress
- Immature and concentrated customer base brings more risk
- The rapid contraction of the cash position reduces the company's financial leeway, although the situation is still good

| Valuation | 2024 e | 2025 e | 2026 e |
|----------------------------|---------------|---------------|---------------|
| Share price | 0.85 | 0.85 | 0.85 |
| Number of shares, millions | 42.6 | 42.6 | 42.6 |
| Market cap | 36 | 36 | 36 |
| EV | 30 | 36 | 39 |
| P/E (adj.) | neg. | neg. | neg. |
| P/E | neg. | neg. | neg. |
| P/FCF | neg. | neg. | neg. |
| P/B | 0.8 | 0.9 | 0.9 |
| P/S | 5.5 | 4.1 | 3.2 |
| EV/Sales | 4.6 | 4.0 | 3.4 |
| EV/EBITDA | neg. | neg. | >100 |
| EV/EBIT (adj.) | neg. | neg. | neg. |
| Payout ratio (%) | 0.0 % | 0.0 % | 0.0 % |
| Dividend yield-% | 0.0 % | 0.0 % | 0.0 % |
| | | | |

Investment profile

- 1. High-tech laser company aiming to get back on track for profitable growth
- 2. Strategic focus on medicine and biomedicine
- The company is aiming for a scalable operating model and per-treatment billing
- 4. A strong cash position provides room for maneuver and a buffer against losses
- 5. Evidence still needed on the effectiveness and profitability of the project model

Potential



- · A defensive market with growth well into the future
- The company's technological expertise, ability to tailor products and build cloud services gives Modulight a competitive advantage
- A model based on license fees and pay-per-treatment pricing can be highly scalable if successful

Risks



- The project-based model has been unreliable, at least for 2022-2023, and we believe its long-term performance requires further evidence.
- Revenue and profitability are poorly predictable
- Low visibility of projects and their progress
- Immature and concentrated customer base brings more risk

Revenue was known – result fell clearly below the forecasts

Estimates vs. outcome Q4'23

- Q4 revenue was 1.0 MEUR and full year 2023 revenue was 4.0 MEUR
- 2023 revenue decreased by -12% compared to the previous year (2022: 4.6 MEUR).
- · Last year's revenue was a clear disappointment both compared to the company's targets (strong growth) and our forecasts.
- According to Modulight, the reason for the decrease was project delays beyond the control of the company and shifting to a treatment-specific business model.
- Q4 EBIT was -5.1 MEUR and -12.1 MEUR for the full year (2022: -7.8 MEUR).
- EBIT was clearly below our expectations. The primary reason was significantly increased depreciation of -2.1 MEUR (Q4'22: -0.5 MEUR).
- The cost level was also slightly higher than we expected, which contributed to the forecast undershoot.
- Cash flow from operating activities in 2023 was -7.3 MEUR and cash flow from investments was -9.7 MEUR.
- Due to high investments and too low revenue, the business was heavily in the red. According to the management, the decrease in investments should be reflected positively in the figures during 2024.
- Net cash assets decreased from 35.6 MEUR in the previous year to 18.6 MEUR at the end of the year
- The company's balance sheet is still very strong, but cash assets have contracted sharply and we expect losses to continue, which reduces the financial leeway.
- On Friday, the Finnish newspaper Aamulehti published an article about the Finnish Financial Supervisory Authority's previous investigation and subsequent comments to Modulight, which was new information to the market. The company did not comment on this invoking the confidentiality of the report. However, the report is public except for certain sections.

| Estimates MEUR / EUR | Q4'22 Comparison | Q4'23 Actualized | Q4'23e Inderes | Q4'23e Consensus | Cons | ensus High | Difference (%) Act. vs. inderes | 2023e Inderes |
|----------------------|---------------------|---------------------|-------------------|---------------------|------|---------------|---------------------------------|------------------|
| Revenue | 1.3 | 1.0 | 1.0 | | | | 2% | 4.0 |
| EBIT | -2.5 | -5.1 | -2.3 | | | | 120% | -12.1 |
| EPS (reported) | -0.06 | -0.12 | -0.05 | | | | 133% | |
| | | | | | | | | |
| Revenue growth-% | -86.0 % | -19.6 % | -21.1 % | | | | 1,6 pp | |
| EBIT-% (adj.) | -197.4 % | -496.5 % | -229.7 % | | | | -266,8 pp | |

Source: Inderes

Watch the Q4 webcast



We cut both revenue and earnings forecasts

Estimate revisions 2024e-2025e

- We cut our revenue forecasts for the coming years by approximately 20% based on the delay in commercializations.
- We also expected a short-term boost for phase III projects, which does not seem to materialize, and the projects are likely to be realized in the longer term.
- Our earnings forecasts fell sharply. However, this is mainly due to depreciation that we raised quite a bit.
- At EBITDA level, our forecasts are also clearly decreasing, mainly due to the lower revenue level.
- We expect cash flow from operating activities to be approximately EUR
 7-8 MEUR in the red in 2024.

| Estimate revisions MEUR / EUR | 2023e Old | 2023e New | Change % | 2024e Old | 2024e New | Change % | 2025e Old | 2025e New | Change % |
|-------------------------------|--------------|--------------|-------------|--------------|--------------|-------------|--------------|--------------|-------------|
| Revenue | 4.0 | 4.0 | 0% | 8.0 | 6.5 | -18% | 11.2 | 8.8 | -21% |
| EBIT | -9.4 | -12.1 | 30% | -3.4 | -10.5 | 206% | -2.1 | -5.5 | 164% |
| EPS (excl. NRIs) | -0.21 | -0.28 | 30% | -0.08 | -0.24 | 209% | -0.04 | -0.10 | 172% |
| DPS | 0.00 | 0.00 | | 0.00 | 0.00 | | 0.00 | 0.00 | |

Valuation requires support from concrete growth

EV/S ratios are roughly indicative of the stock's neutral pricing

Because of the loss-making business, we cannot use earnings-based multiples in valuation, but rely on revenue-based EV/S ratios and DCF calculation that models the present value of future cash flows. The valuation is imprecise in nature, since it relies on forecasts to which there is practically no visibility.

Based on revenue, the valuation of the stock is mainly unchanged from the previous update, as the price drop has been of the same magnitude as the forecast drops. With our updated estimates, EV/S ratios for 2024-2025 are 4.4x and 4.0x. The ratios are high compared to Lumibird SA which we consider the most suitable peer (EV/S: 1.8x and 1.6x). The median of the laser manufacturer peer group is 2.2x-2.4x and the median of medical device manufacturers is 4.9x-4.6x.

Given the business development and low visibility, our view on the stock's acceptable 2024e EV/S multiple range is 3x-5x. The stock is thus roughly priced correctly relative to growth forecasts. We underline the significant uncertainty in the forward-looking projections, which is why we are cautious about drawing conclusions based on projections for the coming years.

DCF does not indicate upside for the stock

The baseline scenario in our DCF calculation falls to EUR 1.2 (was 1.4). The decrease is explained by forecast changes and increased cost of capital. In the positive scenario, the DCF is EUR 2.8 and in the negative scenario EUR 0.5. The main factor explaining the differences between the scenarios is revenue growth, which is followed by profitability. In particular,

the higher terminal profitability (EBIT of 30%) used in the positive scenario has a clear upward effect on the value. In the negative scenario, terminal profitability remains at 20%. We note that the scenarios do not represent our view of the best and worst possible path for the business but are intended to provide investors with a perspective on the sensitivity of the valuation assumptions used, which in the case of Modulight is high. More information on the scenarios can be found in the Initiation of coverage report.


We repeat our recommendations as the loss and fuzzy outlook overshadow the future

We reiterate our Reduce recommendation and lower our target price to EUR 0.9 (was 1.2) as the valuation picture weakened with estimate revisions. Our view on the fair value of Modulight's share is EUR 0.8-1.4. Given the company's profile, significant estimate risk and low visibility, we believe a relatively wide fair value range is justified. Central to the view are the EV/S ratio and DCF model and its scenarios, which suggest that the stock is quite modestly priced with the assumptions of our neutral scenario. The DCF suggests a significant upside or downside for the share in high and low growth scenarios. In case the low estimate materializes, the risk of permanently losing capital is considerable. Currently, we find the stock expensive relative to the peers. On the other hand, the DCF model indicates a reasonable upside. However, the current heavy loss-making, combined with poor visibility in terms of growth, leaves the risk/reward ratio modest for the time being.

| Valuation | 2024e | 2025 e | 2026 e |
|----------------------------|-------|---------------|---------------|
| Share price | 0.85 | 0.85 | 0.85 |
| Number of shares, millions | 42.6 | 42.6 | 42.6 |
| Market cap | 36 | 36 | 36 |
| EV | 30 | 36 | 39 |
| P/E (adj.) | neg. | neg. | neg. |
| P/E | neg. | neg. | neg. |
| P/FCF | neg. | neg. | neg. |
| P/B | 0.8 | 0.9 | 0.9 |
| P/S | 5.5 | 4.1 | 3.2 |
| EV/Sales | 4.6 | 4.0 | 3.4 |
| EV/EBITDA | neg. | neg. | >100 |
| EV/EBIT (adj.) | neg. | neg. | neg. |
| Payout ratio (%) | 0.0 % | 0.0 % | 0.0 % |
| Dividend yield-% | 0.0 % | 0.0 % | 0.0 % |

Source: Inderes

EV/S ratios



Business development graphs


Revenue and EBIT, MEUR



Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23

Revenue EBIT

Cash equivalents, MEUR



Development of the number of projects



Valuation table

| Number of shares, millions 42.6 <th< th=""><th>2022 2023 2024e 2025e 2026e 2027e</th><th>20</th><th>2023</th><th>2022</th><th>2021</th><th>Valuation 20</th></th<> | 2022 2023 2024e 2025e 2026e 2027e | 20 | 2023 | 2022 | 2021 | Valuation 20 |
|---|---|----|-------|-------|-------|-------------------------------|
| Market cap 484 126 38 36 36 36 36 EV 430 90 20 30 36 39 47 P/E (adj.) neg. neg. <t< th=""><th>2.95 0.90 0.85 0.85 0.85 0.85</th><th>0</th><th>0.90</th><th>2.95</th><th>11.4</th><th>Share price</th></t<> | 2.95 0.90 0.85 0.85 0.85 0.85 | 0 | 0.90 | 2.95 | 11.4 | Share price |
| EV 430 90 20 30 36 39 47 P/E (adj.) neg. neg. <th>42.6 42.6 42.6 42.6 42.6 42.6</th> <th>4:</th> <th>42.6</th> <th>42.6</th> <th>42.6</th> <th>Number of shares, millions 42</th> | 42.6 42.6 42.6 42.6 42.6 42.6 | 4: | 42.6 | 42.6 | 42.6 | Number of shares, millions 42 |
| P/E (adj.) neg. | 126 38 36 36 36 36 | 3 | 38 | 126 | 484 | Market cap 4 |
| P/E neg. | 90 20 30 36 39 41 | 3 | 20 | 90 | 430 | EV 43 |
| P/FCF neg. neg. <t< th=""><th>neg. neg. neg. neg. neg. neg.</th><th>n</th><th>neg.</th><th>neg.</th><th>neg.</th><th>P/E (adj.)</th></t<> | neg. neg. neg. neg. neg. neg. | n | neg. | neg. | neg. | P/E (adj.) |
| P/B 6.4 1.9 0.7 0.8 0.9 0.9 1.0 | neg. neg. neg. neg. neg. neg. | n | neg. | neg. | neg. | P/E ne |
| | neg. neg. neg. neg. neg. neg. | n | neg. | neg. | neg. | P/FCF ne |
| | 1.9 0.7 0.8 0.9 0.9 1.0 | C | 0.7 | 1.9 | 6.4 | P/B 6 |
| P/S 53.3 27.3 9.5 5.5 4.1 3.2 2.4 | 27 .3 9.5 5.5 4.1 3.2 2.4 | 5 | 9.5 | 27.3 | 53.3 | P/S 55 |
| EV/Sales 47.4 19.6 4.9 4.6 4.0 3.4 2.3 | 19.6 4.9 4.6 4.0 3.4 2.7 | 4 | 4.9 | 19.6 | 47.4 | EV/Sales 47 |
| EV/EBITDA >100 neg. neg. neg. neg. >100 16. | neg. neg. neg. neg. >100 16.3 | n | neg. | neg. | >100 | EV/EBITDA >1 |
| EV/EBIT (adj.) neg. neg. neg. neg. neg. neg. neg. neg. | neg. neg. neg. neg. neg. neg. | n | neg. | neg. | neg. | EV/EBIT (adj.) |
| Payout ratio (%) 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % | 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % | 0. | 0.0 % | 0.0 % | 0.0 % | Payout ratio (%) |
| Dividend yield-% 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % | 0.0 % 0.0 % 0.0 % 0.0 % | 0. | 0.0 % | 0.0 % | 0.0 % | Dividend yield-% 0.0 |

Income statement

| Income statement | 2022 | Q1'23 | Q2'23 | Q3'23 | Q4'23 | 2023 | Q1'24e | Q2'24e | Q3'24e | Q4'24e | 2024e | 2025 e | 2026 e | 2027 e |
|------------------------|----------|----------|---------|----------|----------|----------|----------|----------|----------|----------|----------|---------------|---------------|---------------|
| Revenue | 4.6 | 1.5 | 1.0 | 0.5 | 1.0 | 4.0 | 1.3 | 1.5 | 1.8 | 2.0 | 6.5 | 8.8 | 11.5 | 14.9 |
| Group | 4.6 | 1.5 | 1.0 | 0.5 | 1.0 | 4.0 | 1.3 | 1.5 | 1.8 | 2.0 | 6.5 | 8.8 | 11.5 | 14.9 |
| EBITDA | -5.9 | -1.2 | -0.3 | -4.8 | -2.2 | -8.5 | -1.8 | -1.8 | -1.8 | -1.8 | -7.3 | -2.1 | 0.0 | 2.5 |
| Depreciation | -1.9 | -0.7 | 0.1 | -0.2 | -2.9 | -3.6 | -0.8 | -0.8 | -0.8 | -0.8 | -3.2 | -3.4 | -3.3 | -3.2 |
| EBIT | -7.8 | -1.9 | -0.2 | -5.0 | -5.1 | -12.1 | -2.6 | -2.6 | -2.6 | -2.6 | -10.5 | -5.5 | -3.3 | -0.7 |
| Net financial items | -0.8 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | -0.1 |
| PTP | -8.6 | -1.9 | -0.1 | -4.9 | -5.0 | -11.8 | -2.6 | -2.6 | -2.6 | -2.6 | -10.3 | -5.4 | -3.2 | -0.8 |
| Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.6 | 0.2 |
| Net earnings | -8.6 | -1.9 | -0.1 | -4.9 | -5.0 | -11.8 | -2.6 | -2.6 | -2.6 | -2.6 | -10.3 | -4.3 | -2.6 | -0.7 |
| EPS (adj.) | -0.20 | -0.04 | 0.00 | -0.11 | -0.12 | -0.28 | -0.06 | -0.06 | -0.06 | -0.06 | -0.24 | -0.10 | -0.06 | -0.02 |
| EPS (rep.) | -0.20 | -0.04 | 0.00 | -0.11 | -0.12 | -0.28 | -0.06 | -0.06 | -0.06 | -0.06 | -0.24 | -0.10 | -0.06 | -0.02 |
| | | | | | | | | | | | | | | |
| Key figures | 2022 | Q1'23 | Q2'23 | Q3'23 | Q4'23 | 2023 | Q1'24e | Q2'24e | Q3'24e | Q4'24e | 2024e | 2025 e | 2026 e | 2027 e |
| Revenue growth-% | -49.3 % | -6.7 % | 101.4 % | -58.9 % | -19.6 % | -12.5 % | -12.6 % | 49.1% | 248.3 % | 92.0 % | 62.1% | 35.0 % | 30.0 % | 30.0 % |
| Adjusted EBIT growth-% | 935.2 % | 0.2 % | -87.8 % | 174.6 % | 102.3 % | 55.7 % | 39.1% | 1277.2 % | -47.3 % | -48.2 % | -13.2 % | -47.8 % | -39.9 % | -77.5 % |
| EBITDA-% | -129.0 % | -83.3 % | -33.6 % | -943.7 % | -213.5 % | -212.0 % | -141.4 % | -122.8 % | -103.5 % | -93.1% | -112.4 % | -23.6 % | 0.3 % | 16.8 % |
| Adjusted EBIT-% | -169.5 % | -127.5 % | -19.1 % | -983.2 % | -496.5 % | -301.4 % | -202.7 % | -176.1 % | -148.8 % | -133.9 % | -161.4 % | -62.4 % | -28.9 % | -5.0 % |
| Net earnings-% | -185.9 % | -124.1 % | -9.7 % | -964.6 % | -487.3 % | -293.1% | -198.9 % | -172.8 % | -146.0 % | -131.4 % | -158.4 % | -49.0 % | -22.4 % | -4.5 % |

Balance sheet

| Assets | 2022 | 2023 | 2024 e | 2025 e | 2026e |
|--------------------------|------|------|---------------|---------------|-------|
| Non-current assets | 27.7 | 33.8 | 35.1 | 36.3 | 37.5 |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 7.7 | 8.9 | 8.8 | 10.0 | 11.0 |
| Tangible assets | 19.9 | 24.9 | 26.3 | 26.3 | 26.5 |
| Associated companies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other non-current assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Deferred tax assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current assets | 50.7 | 30.2 | 22.6 | 16.0 | 12.3 |
| Inventories | 2.3 | 2.6 | 2.4 | 2.6 | 2.5 |
| Other current assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Receivables | 4.5 | 2.5 | 2.6 | 2.7 | 2.9 |
| Cash and equivalents | 43.9 | 25.1 | 17.6 | 10.6 | 6.9 |
| Balance sheet total | 78.3 | 64.0 | 57.7 | 52.2 | 49.8 |

| Liabilities & equity | 2022 | 2023 | 2024e | 2025e | 2026e |
|-----------------------------|------|-------|-------|-------|-------|
| Equity | 67.6 | 55.7 | 45.4 | 41.1 | 38.5 |
| Share capital | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Retained earnings | -7.8 | -19.7 | -30.0 | -34.4 | -36.9 |
| Hybrid bonds | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revaluation reserve | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other equity | 75.3 | 75.3 | 75.3 | 75.3 | 75.3 |
| Minorities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Non-current liabilities | 6.6 | 4.5 | 8.6 | 7.4 | 7.3 |
| Deferred tax liabilities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Provisions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest bearing debt | 6.6 | 4.5 | 8.6 | 7.4 | 7.3 |
| Convertibles | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other long term liabilities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current liabilities | 4.1 | 3.7 | 3.7 | 3.8 | 4.0 |
| Interest bearing debt | 1.7 | 2.0 | 2.6 | 2.4 | 2.4 |
| Payables | 2.5 | 1.7 | 1.1 | 1.3 | 1.6 |
| Other current liabilities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Balance sheet total | 78.3 | 63.9 | 57.7 | 52.2 | 49.8 |

DCF calculation

| DCF model | 2023 | 2024e | 2025 e | 2026 e | 2027e | 2028e | 2029 e | 2030e | 2031e | 2032e | 2033 e | 2034e | TERM |
|---|----------|----------|---------------|---------------|--------|--------|---------------|--------|--------|--------|---------------|--------|--------|
| Revenue growth-% | -12.5 % | 62.1% | 35.0 % | 30.0 % | 30.0 % | 25.0 % | 20.0 % | 15.0 % | 10.0 % | 6.0 % | 3.0 % | 3.0 % | 3.0 % |
| EBIT-% | -301.4 % | -161.4 % | -62.4 % | -28.9 % | -5.0 % | 10.0 % | 14.0 % | 18.0 % | 22.0 % | 22.0 % | 22.0 % | 22.0 % | 22.0 % |
| EBIT (operating profit) | -12.1 | -10.5 | -5.5 | -3.3 | -0.7 | 1.9 | 3.1 | 4.6 | 6.2 | 6.6 | 6.8 | 7.0 | |
| + Depreciation | 3.6 | 3.2 | 3.4 | 3.3 | 3.2 | 3.1 | 3.3 | 3.4 | 3.5 | 3.6 | 3.6 | 3.7 | |
| - Paid taxes | 0.0 | 0.0 | 1.1 | 0.6 | 0.2 | -0.4 | -0.6 | -0.9 | -1.2 | -1.3 | -1.3 | -1.3 | |
| - Tax, financial expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| + Tax, financial income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| - Change in working capital | 1.0 | -0.5 | -0.2 | 0.3 | 0.2 | -0.3 | -0.1 | -0.2 | -0.3 | -0.1 | -0.1 | -0.1 | |
| Operating cash flow | -7.5 | -7.8 | -1.2 | 1.0 | 2.9 | 4.3 | 5.7 | 6.9 | 8.2 | 8.7 | 8.9 | 9.1 | |
| + Change in other long-term liabilities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| - Gross CAPEX | -9.7 | -4.5 | -4.6 | -4.6 | -4.6 | -4.6 | -4.6 | -4.6 | -4.6 | -4.6 | -4.6 | 4.5 | |
| Free operating cash flow | -17.3 | -12.3 | -5.8 | -3.6 | -1.7 | -0.3 | 1.1 | 2.3 | 3.6 | 4.1 | 4.3 | 13.7 | |
| +/- Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| FCFF | -17.3 | -12.3 | -5.8 | -3.6 | -1.7 | -0.3 | 1.1 | 2.3 | 3.6 | 4.1 | 4.3 | 13.7 | 149 |
| Discounted FCFF | | -11.2 | -4.7 | -2.6 | -1.1 | -0.2 | 0.5 | 1.0 | 1.4 | 1.5 | 1.4 | 3.8 | 41.4 |
| Sum of FCFF present value | | 31.4 | 42.5 | 47.2 | 49.8 | 50.9 | 51.1 | 50.5 | 49.5 | 48.1 | 46.6 | 45.2 | 41.4 |
| Enterprise value DCF | | 31.4 | | | | | | | | | | | |


| Equity value DCF per share | 1.2 |
|-----------------------------|------|
| Equity value DCF | 50.0 |
| -Dividend/capital return | 0.0 |
| -Minorities | 0.0 |
| + Cash and cash equivalents | 25.1 |
| - Interest bearing debt | -6.5 |
| Enterprise value DCF | 31.4 |

WACC


| Tax-% (WACC) | 20.0 % |
|---|--------|
| Target debt ratio (D/(D+E) | 10.0 % |
| Cost of debt | 8.0 % |
| Equity Beta | 2.14 |
| Market risk premium | 4.75% |
| Liquidity premium | 0.50% |
| Risk free interest rate | 2.5 % |
| Cost of equity | 13.2 % |
| Weighted average cost of capital (WACC) | 12.5 % |


Source: Inderes


Cash flow distribution




DCF sensitivity calculations and key assumptions in graphs









Summary

| Income statement | 2021 | 2022 | 2023 | 2024e | 2025 e | Per share data | 2021 | 2022 | 2023 | 2024 e | 2025 e |
|---------------------------|-------|-------|-------|---------------|---------------|--------------------------|---------|----------|----------|----------------|---------------|
| | 9.1 | 4.6 | | | 8.8 | | | | | | |
| Revenue | | | 4.0 | 6.5 | | EPS (reported) | -0.12 | -0.20 | -0.28 | -0.24 | -0.10 |
| EBITDA | 0.4 | -5.9 | -8.5 | -7.3 | -2.1 | EPS (adj.) | -0.12 | -0.20 | -0.28 | -0.24 | -0.10 |
| EBIT | -0.8 | -7.8 | -12.1 | -10.5 | -5.5 | OCF / share | -0.01 | -0.08 | -0.18 | -0.18 | -0.03 |
| PTP | -5.1 | -8.6 | -11.8 | -10.3 | -5.4 | FCF / share | -0.23 | -0.40 | -0.41 | -0.29 | -0.14 |
| Net Income | -5.1 | -8.6 | -11.8 | -10.3 | -4.3 | Book value / share | 1.79 | 1.59 | 1.31 | 1.06 | 0.96 |
| Extraordinary items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Dividend / share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance sheet | 2021 | 2022 | 2023 | 2024e | 2025 e | Growth and profitability | 2021 | 2022 | 2023 | 2024e | 2025 e |
| Balance sheet total | 87.5 | 78.3 | 64.0 | 57.7 | 52.2 | Revenue growth-% | -10% | -49% | -12% | 62% | 35% |
| Equity capital | 76.2 | 67.6 | 55.7 | 45.4 | 41.1 | EBITDA growth-% | -92% | -1428% | 44% | -14% | -72 % |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | EBIT (adj.) growth-% | -116% | 935% | 56% | -13% | -48% |
| Net debt | -53.4 | -35.6 | -18.6 | -6.4 | -0.7 | EPS (adj.) growth-% | -198% | 69% | 38% | -12 % | -58% |
| | | | | | | EBITDA-% | 4.9 % | -129.0 % | -212.0 % | -112.4 % | -23.6 % |
| Cash flow | 2021 | 2022 | 2023 | 2024 e | 2025 e | EBIT (adj.)-% | -8.3 % | -169.5 % | -301.4 % | -161.4 % | -62.4 % |
| EBITDA | 0.4 | -5.9 | -8.5 | -7.3 | -2.1 | EBIT-% | -8.3 % | -169.5 % | -301.4 % | -161.4 % | -62.4 % |
| Change in working capital | -0.9 | 2.6 | 1.0 | -0.5 | -0.2 | ROE-% | -11.8 % | -11.9 % | -19.1 % | -20.5 % | -10.0 % |
| Operating cash flow | -0.4 | -3.3 | -7.5 | -7.8 | -1.2 | ROI-% | -1.5 % | -9.6 % | -17.6 % | -17.7 % | -10.2 % |
| CAPEX | -9.6 | -13.7 | -9.7 | -4.5 | -4.6 | Equity ratio | 87.0 % | 86.3 % | 87.1% | 78.7 % | 78.6 % |
| Free cash flow | -10.0 | -17.0 | -17.3 | -12.3 | -5.8 | Gearing | -70.1% | -52.7 % | -33.4 % | -14.2 % | -1.7 % |
| Valuation multiples | 2021 | 2022 | 2023 | 2024 e | 2025 e | | | | | | |
| EV/S | 47.4 | 19.6 | 4.9 | 4.6 | 4.0 | | | | | | |

Dividend-%
Source: Inderes

EV/EBITDA (adj.)

EV/EBIT (adj.)

P/E (adj.)

P/B

>100

neg.

neg.

6.4

0.0 %

neg.

neg.

neg.

1.9

0.0 %

neg.

neg.

neg.

0.7

0.0 %

neg.

neg.

neg.

8.0

0.0 %

neg.

neg.

neg.

0.9

0.0 %

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors, Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy The 12-month risk-adjusted expected shareholder return of the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

Reduce The 12-month risk-adjusted expected shareholder return of the share is weak

Sell The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

| Date | Recommendation | Target | Share price |
|-----------|----------------|--------|-------------|
| 3/15/2023 | Reduce | 2.30 € | 2.42 € |
| 5/2/2023 | Reduce | 2.30 € | 2.31 € |
| 8/11/2023 | Reduce | 2.30 € | 2.15 € |
| 8/21/2023 | Reduce | 1.60 € | 1.50 € |
| 20.1023 | Reduce | 1.50 € | 1.39 € |
| 1/2/2023 | Reduce | 1.20 € | 1.17 € |
| 2/26/2024 | Reduce | 0.90 € | 0.85 € |



Inderes democratizes investor information by connecting investors and listed companies.

We help over 400 listed companies better serve investors. Our investor community is home to over 70,000 active members.

We build solutions for listed companies that enable frictionless and effective investor relations. For listed companies, we offer Commissioned Research, IR Events, AGMs, and IR Software.

Inderes is listed on the Nasdaq First North growth market and operates in Finland, Sweden, Norway, and Denmark.

Inderes Oyj

Itämerentori 2 FI-00180 Helsinki, Finland +358 10 219 4690

Award-winning research at inderes.fi







Juha Kinnunen 2012, 2016, 2017, 2018, 2019, 2020



Mikael Rautanen 2014, 2016, 2017, 2019



Sauli Vilén 2012, 2016, 2018, 2019, 2020



Antti Viljakainen 2014, 2015, 2016, 2018, 2019, 2020



Olli Koponen 2020



Joni Grönqvist 2019, 2020



Erkki Vesola 2018, 2020



Petri Gostowski 2020



Atte Riikola 2020

Connecting investors and listed companies.